Daiichi Sankyo Deutschland GmbH
Industry / private company
Location:
München,
Germany (DE)
ISNI: 0000000406235599
ROR: https://ror.org/01qhj1g70
Show on Map:
Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) (2022)
Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, Fasching P, Iwata H
Conference contribution
Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice (2015)
Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder R
Journal article
Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide (2014)
Bramlage P, Ketelhut R, Fronk EM, Wolf WP, Smolnik R, Zemmrich C, Schmieder R
Journal article